Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Switch OTC Versions of Pemirolast K Recommended for Approval
August 29, 2011
- BI Licenses ADCC Enhancing Technology from ProBioGen
August 29, 2011
- Caffeine Citrate Designated as an Orphan Drug
August 29, 2011
- JAMS Opposes Switch OTC Status for 3 Drugs Including Acarbose
August 29, 2011
- Eisai Establishes Marketing Subsidiary in Mexico
August 29, 2011
- JGA to Ask for Retention of “70% Rule”in Pricing of “First Generics”
August 29, 2011
- Mr Wolf of PhRMA Explains Advantages of VICP Introduced in US
August 29, 2011
- Shionogi Acquires 24.17% Stake in C&O of China
August 29, 2011
- Kyowa Pharm. Ind. Seeking M&A to Expand Product Line-up
August 29, 2011
- Saitama Police Send Case to Public Prosecutors Office against President of Saitama Pharm. Association
August 29, 2011
- Female Life Expectancy Down Slightly in 2010; First Decline in 5 Years
August 15, 2011
- PMDA to Initiate Clinical Trial Consultation for Orphan Drugs
August 15, 2011
- Takeda Discontinues Development of Anti-obesity Drug in US
August 15, 2011
- Growth in Diabetes Drug Market Driven by DPP-4 Inhibitors in 2010: Yano Research
August 15, 2011
- JPA President Kodama to Explain about Leaked Copy of His Appeal at General Assembly
August 15, 2011
- NCCHD Creates Pediatric Clinical Trial Network of 27 Facilities
August 15, 2011
- MSD Invites Former JPMA Director General as Compliance Adviser
August 15, 2011
- Kowa Obtains Marketing Approval for Pitavastatin in Mexico
August 15, 2011
- Gov't Council Submits 4th Science & Technology Basic Plan
August 15, 2011
- Kyowa Kirin Aims for 70% Increase in Sales for UK Subsidiary ProStrakan by 2013
August 15, 2011
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…